Skip to main content

EMBLEM™ MRI S-ICD System

Subcutaneous Implantable Defibrillator

Pre-clinical data

Explore the articles below for pre-clinical data evaluating the use of Modular CRM (mCRM™) Systems* in animal subjects. NOTE: You may need a subscription to read the full articles. The 6-month MODULAR ATP clinical trial results are now available.

*Caution: Investigational device. Limited by US law to investigational use only. Not available for sale.

Key Resources

EMBLEM S-ICD Indications, Safety and Warnings
View MODULAR ATP trial results
Request More information

Request More Information

Results at a glance

100% Chronic mCRM Communication Success Rate.
Chronic mCRM Communication Success Rate1
0.72V @ 0.5ms - Acceptable Pacing Capture Thresholds at 90 Days.
@ 0.5ms - Acceptable Pacing Capture Thresholds at 90 Days2
 

Pre-Clinical Articles

Device-device communication stability of leadless anti-tachycardia pacemaker and subcutaneous implantable cardioverter defibrillator over 18 months
Tjong, F.V.Y., et al. | Heart Rhythm | 2020
Read Article

Acute and chronic retrieval of a leadless cardiac pacemaker from the right ventricle
Tjong, F.V.Y., et al. | Heart Rhythm | 2019
Read Article

The modular cardiac rhythm management system: the EMPOWER Leadless Pacemaker and the EMBLEM subcutaneous ICD
Tjong, F.V.Y., et al. | Herzschr Elektrophys | 2018
Read Article

Device orientation of a leadless pacemaker and subcutaneous implantable cardioverter-defibrillator in canine and human subjects and the effect on intrabody communication 
Quast, A.B.E., et al. | EP Europace | 2018
Read Article

Acute and 3-Month Performance of a Communicating Leadless Antitachycardia Pacemaker and Subcutaneous Implantable Defibrillator
Tjong, F.V.Y., et al. | JACC Clin Electrophysiol | 2017
Read Article

 
MODULAR ATP Trial. See the data.
 
 
mCRM technology

mCRM technology

Discover how a modular approach to ICD therapy may reduce the risks of TV leads while providing pacing if needed.

Button
MODULAR ATP trial

MODULAR ATP trial

Learn about the MODULAR ATP clinical trial design, primary effectiveness and safety endpoints, timelines and more.

Button
Trial eligibility

Trial eligibility

Explore patient inclusion and exclusion criteria.

Button
 

References

1. Tjong FV, Knops R, Koop B, Soltis B, Brisben AJ, Swackhamer B, Burke MC. Device-device communication stability of leadless anti-tachycardia pacemaker and subcutaneous implantable cardioverter defibrillator over 18 months. Heart Rhythm 2020;17(5 Supplement):s11.https://doi.org/10.1016/j.hrthm.2020.04.005

2. Tjong FVY, Brouwer TF, Koop B, Soltis B, Shuros A, Schmidt B, Swackhamer B, Quast AEB, Wilde AAM, Burke MC, Knops RE. Acute and 3-Month Performance of a Communicating Leadless Antitachycardia Pacemaker and Subcutaneous Implantable Defibrillator. JACC Clin Electrophysiol. 2017 Dec 26;3(13):1487-1498. doi: 10.1016/j.jacep.2017.04.002. Epub 2017 May 31.

Top